SI
MRNS

Sofinnova Investments’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Sofinnova Investments’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,386,177
Closed -$7.72M – 78
2024
Q3 		$7.72M Buy
4,386,177
+234,601
+6% +$327K 0.61% 36
2024
Q2 		$4.86M Buy
4,151,576
+2,750,523
+196% +$6.88M 0.25% 56
2024
Q1 		$12.7M Sell
1,401,053
-371,646
-21% -$3.61M 0.71% 34
2023
Q4 		$19.3M Buy
1,772,699
+787,093
+80% +$5.9M 1.08% 22
2023
Q3 		$7.93M Buy
985,606
+22,987
+2% +$191K 0.5% 40
2023
Q2 		$10.5M Sell
962,619
-237,770
-20% -$2.04M 0.68% 31
2023
Q1 		$8.28M Buy
+1,200,389
New +$7.53M 0.53% 34
2022
Q1 		– Sell
-171,338
Closed -$2.04M – 81
2021
Q4 		$2.04M Buy
171,338
+4,627
+3% +$53.4K 0.12% 63
2021
Q3 		$1.9M Sell
166,711
-179,449
-52% -$2.47M 0.11% 66
2021
Q2 		$6.21M Sell
346,160
-24,191
-7% -$389K 0.36% 45
2021
Q1 		$5.73M Buy
370,351
+96,324
+35% +$1.39M 0.34% 47
2020
Q4 		$3.34M Buy
+274,027
New +$3.82M 0.2% 56

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments's MRNS Position: Q4 2024 in Review

Sofinnova Investments sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 4,386,177 shares — an estimated $7.72M sold.

Sofinnova Investments first reported a position in MRNS in Q4 2020 and held it in 12 quarters. The position peaked at $19.3M in Q4 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Sofinnova Investments reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Sofinnova Investments sold 4,386,177 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $7.72M.
  • Sofinnova Investments first reported a position in Marinus Pharmaceuticals, Inc in Q4 2020 and held it in 12 quarters.
  • Sofinnova Investments's Marinus Pharmaceuticals, Inc position peaked at $19.3M in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.